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Abstract 
Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency characterized 
by thrombocytopenia, eczema, high susceptibility to develop autoimmune manifestations and 
malignancies. Although thrombocytopenia is one of the main causes of death, the 
pathogenesis of platelet (PLT) defect is poorly understood. Here, we evaluated the role of 
WAS protein (WASp) in PLTs in a new conditional mouse model (CoWas) lacking WASp 
only in the megakaryocytic (MK) lineage.We observed an increased number of MKs and 
their progenitors both in CoWas mice and complete Was-/- mice (WKO), as well as normal in 
vitro PLT production by Was-/- MKs. Upon in vivo depletion of PLTs, WKO and CoWas 
mice are able to restore PLT count with kinetics comparable to wild-type (WT) mice, 
suggesting no defect in thrombopoiesis. Of note, WASp-deficient PLTs both in WKO and 
CoWas mice have a shorter half-life and hyper-activated status before and after ADP 
stimulation and are more prone to apoptosis. We also found that WKO and CoWas mice 
develop anti-PLT autoantibodies against Was-/- PLTs in line with different proteomic profile. 
Was-/- PLTs show decreased metabolic activity, increased ubiquitination pathways and 
Immunoglobulin content. Moreover, Was-/- PLTs release higher amount of soluble CD40L 
and are able to induce B-cells activation in vitro culture. Finally, WAS patients show 
increased CD62P and PAC1 expression at steady state and higher sCD40L plasma levels. The 
activation profile of human PLTs improves after LV-gene therapy treatment, in all the 
patients, especially in those with a follow up longer than two years. 
 
